What happens if I overdose Hydrocortisone Bepharbel?
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local, or emergency room immediately.
Proper storage of Hydrocortisone Bepharbel solution:
Hydrocortisone Bepharbel solution is usually handled and stored by a health care provider. If you are using Hydrocortisone Bepharbel solution at home, store Hydrocortisone Bepharbel solution as directed by your pharmacist or health care provider. Keep Hydrocortisone Bepharbel solution out of the reach of children and away from pets.
Overdose of Hydrocortisone Bepharbel in details
Reports of acute toxicity and/or death following overdosage of glucocorticoids are rare. In the event of overdosage, no specific antidote is available, treatment is supportive and symptomatic.
The intraperitoneal LD50 of Hydrocortisone Bepharbel in female mice was 1740 mg/kg.
What should I avoid while taking Hydrocortisone Bepharbel?
Avoid being near people who are sick or have infections. Call your doctor for preventive treatment if you are exposed to chicken pox or measles. These conditions can be serious or even fatal in people who are using steroid medication.
Do not receive a "live" vaccine while you are being treated with Hydrocortisone Bepharbel. Vaccines may not work as well while you are taking a steroid.
Avoid drinking alcohol while you are taking Hydrocortisone Bepharbel.
Hydrocortisone Bepharbel warnings
Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression
Systemic effects of topical corticosteroids may include reversible HPA axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria.
Studies conducted in pediatric subjects demonstrated reversible HPA axis suppression after use of Hydrocortisone Bepharbel Butyrate. Pediatric patients may be more susceptible than adults to systemic toxicity from equivalent doses of Hydrocortisone Bepharbel Butyrate due to their larger skin surface-to-body-mass ratios.
Patients applying a topical corticosteroid to a large surface area or to areas under occlusion should be considered for periodic evaluation of the HPA axis. This may be done by using cosyntropin (ACTH1-24) stimulation testing (CST).
If HPA axis suppression is noted, the frequency of application should be reduced or the drug should be withdrawn, or a less potent corticosteroid should be substituted. Signs and symptoms of glucocorticosteroid insufficiency may occur, requiring supplemental systemic corticosteroids.
Concomitant Skin Infections
If skin infections are present or develop, an appropriate antifungal, antibacterial or antiviral agent should be used. If a favorable response does not occur promptly, use of Hydrocortisone Bepharbel Butyrate should be discontinued until the infection has been adequately controlled.
Skin Irritation
Hydrocortisone Bepharbel Butyrate may cause local skin adverse reactions.
If irritation develops, Hydrocortisone Bepharbel Butyrate should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noticing a clinical exacerbation. Such an observation should be corroborated with appropriate patch testing.
What should I discuss with my healthcare provider before taking Hydrocortisone Bepharbel?
Some medical conditions may interact with Hydrocortisone Bepharbel enema. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
- if you are pregnant, planning to become pregnant, or are breast-feeding
- if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
- if you have allergies to medicines, foods, or other substances
- if you have a weakened immune system; a parasitic, bacterial, fungal, or viral infection; heart failure; diabetes; diarrhea; swelling of the esophagus; stomach problems; blockage of the bowel or other bowel problems; abnormal blood electrolyte (eg, potassium, sodium) levels; measles; tuberculosis (TB); chickenpox; shingles; or herpes infection of the eye; or if you have received a recent vaccination
- if you have a history of glaucoma, cataracts, or other eye problems; high blood pressure; weak bones; heart attack; ulcers; kidney problems; liver problems (eg, cirrhosis); underactive thyroid; nerve problems (eg, myasthenia gravis); or a positive TB skin test
Some MEDICINES MAY INTERACT with Hydrocortisone Bepharbel enema. Tell your health care provider if you are taking any other medicines, especially any of the following:
- Aprepitant, clarithromycin, or hormonal contraceptives (eg, birth control pills) because they may increase the risk of Hydrocortisone Bepharbel enema's side effects
- Barbiturates (eg, phenobarbital), carbamazepine, hydantoins (eg, phenytoin), or rifampin because they may decrease Hydrocortisone Bepharbel enema's effectiveness
- Anticoagulants (eg, warfarin), ritodrine, or smallpox vaccine because the risk of their side effects may be increased by Hydrocortisone Bepharbel enema
- Interleukin-2 or mifepristone because their effectiveness may be decreased by Hydrocortisone Bepharbel enema
This may not be a complete list of all interactions that may occur. Ask your health care provider if Hydrocortisone Bepharbel enema may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Hydrocortisone Bepharbel precautions
Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression
Systemic effects of topical corticosteroids may include reversible HPA axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria.
Studies conducted in pediatric subjects demonstrated reversible HPA axis suppression after use of Hydrocortisone Bepharbel Butyrate. Pediatric patients may be more susceptible than adults to systemic toxicity from equivalent doses of Hydrocortisone Bepharbel Butyrate due to their larger skin surface-to-body-mass ratios.
Patients applying a topical corticosteroid to a large surface area or to areas under occlusion should be considered for periodic evaluation of the HPA axis. This may be done by using cosyntropin (ACTH1-24) stimulation testing (CST).
If HPA axis suppression is noted, the frequency of application should be reduced or the drug should be withdrawn, or a less potent corticosteroid should be substituted. Signs and symptoms of glucocorticosteroid insufficiency may occur, requiring supplemental systemic corticosteroids.
Concomitant Skin Infections
If skin infections are present or develop, an appropriate antifungal, antibacterial or antiviral agent should be used. If a favorable response does not occur promptly, use of Hydrocortisone Bepharbel Butyrate should be discontinued until the infection has been adequately controlled.
Skin Irritation
Hydrocortisone Bepharbel Butyrate may cause local skin adverse reactions.
If irritation develops, Hydrocortisone Bepharbel Butyrate should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noticing a clinical exacerbation. Such an observation should be corroborated with appropriate patch testing.
What happens if I miss a dose of Hydrocortisone Bepharbel?
Call your doctor for instructions if you miss an appointment for your Hydrocortisone Bepharbel injection.
References
- DailyMed. "CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DrugBank. "hydrocortisone". http://www.drugbank.ca/drugs/DB00741 (accessed September 17, 2018).
- MeSH. "Anti-Inflammatory Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology